Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry

Recurrent glioblastoma multiforme (GBM), insensitive against most therapeutic interventions, has low response and survival rates. Temozolomide (TMZ) was approved for second-line therapy of recurrent anaplastic astrocytoma. However, TMZ therapy in GBM patients reveals properties such as reduced toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Klaus, Wiessler, Manfred, Ehemann, Volker, Pipkorn, Ruediger, Spring, Herbert, Debus, Juergen, Didinger, Bernd, Koch, Mario, Muller, Gabriele, Waldeck, Waldemar
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761188/
https://www.ncbi.nlm.nih.gov/pubmed/19920915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761188/
https://www.ncbi.nlm.nih.gov/pubmed/19920915

Ejemplares similares